Sai Life Sciences Limited (NSE:SAILIFE)

India · Delayed Price · Currency is INR

1,126.00

+10.40 (0.93%)

May 11, 2026, 3:30 PM IST

59.74% (1Y)

Market Cap	238.78B +58.8%
Revenue (ttm)	21.70B +39.6%
Net Income	3.33B +141.3%
EPS	15.54 +111.9%
Shares Out	212.02M
PE Ratio	72.49
Forward PE	58.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	634,205
Average Volume	555,288
Open	1,120.00
Previous Close	1,115.60
Day's Range	1,102.00 - 1,139.40
52-Week Range	707.00 - 1,139.40
Beta	n/a
RSI	72.63
Earnings Date	May 14, 2026

About Sai Life Sciences

Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India. [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 1999

Employees 3,401

Stock Exchange National Stock Exchange of India

Ticker Symbol SAILIFE

Full Company Profile

Financial Performance

In fiscal year 2025, Sai Life Sciences's revenue was 16.95 billion, an increase of 15.66% compared to the previous year's 14.65 billion. Earnings were 1.70 billion, an increase of 105.45%.

Financial Statements

News

Sai Life Sciences Transcript: Q3 25/26

Q3 FY 2026 saw 27% revenue and 86% profit growth year-over-year, with strong margin expansion and robust performance in both CDMO and CRO segments. Strategic investments in capacity, technology, and portfolio diversification support sustained growth and margin guidance of 28%-30%.

3 months ago - Transcripts

Sai Life Sciences Transcript: Q2 25/26

Q2 FY26 saw robust revenue and margin growth, driven by strong CDMO and CRO performance, expanded capabilities in new modalities, and strategic investments in capacity and technology. The outlook remains positive with a focus on sustainable, diversified growth and ongoing capacity expansion.

6 months ago - Transcripts

Sai Life Sciences Transcript: Q1 25/26

Q1 FY26 saw 77% revenue growth and a 305% rise in EBITDA, driven by strong CDMO and CRO performance, capacity expansion, and strategic investments. Capacity utilization reached 77%, with no one-offs in results, and the company remains optimistic about sustained growth and industry trends.

9 months ago - Transcripts

Sai Life Sciences Transcript: Q4 24/25

Fiscal 2025 delivered 16% revenue growth and 42% EBITDA growth, with margins expanding to 25%. Robust performance was driven by strong CDMO and CRO momentum, capacity expansion, and a one-time INR 34 crore provision. Long-term guidance targets 28%-30% EBITDA margin and 15%-20% revenue CAGR.

1 year ago - Transcripts

Sai Life Sciences Transcript: Q3 24/25

Q3 FY 2025 saw 15% revenue growth and 19% EBITDA growth year-over-year, with margin expansion and strong cash flow. The company targets 15%-20% revenue CAGR and 28%-30% EBITDA margin over 3-5 years, supported by ongoing capacity expansion and debt reduction.

1 year ago - Transcripts